Results 351 to 360 of about 185,125 (388)

Refractory anaemia in a patient with end‐stage heart failure secondary to aortic stenosis

ESC Heart Failure, EarlyView.
Jiayu Liang, Suxin Luo, Bi Huang
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry

Alimentary Pharmacology and Therapeutics, 2020
Proton pump inhibitors (PPIs) are the most commonly used first‐line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE are still unknown.
E. Laserna-Mendieta, S. Casabona, D. Guagnozzi, E. Savarino, A. Perelló, A. Guardiola-Arévalo, J. Barrio, I. Pérez-Martínez, Anne Lund Krarup, J. Alcedo, S. de la Riva, Esther Rey-Iborra, C. Santander, Á. Arias, A. Lucendo   +14 more
semanticscholar   +1 more source

Endoscopic treatment of proton pump inhibitor‐refractory gastroesophageal reflux disease with anti‐reflux mucosectomy: Experience of 109 cases

Digestive Endoscopy, 2020
Some patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) therapy. Anti‐reflux mucosectomy (ARMS) is a minimally invasive endoscopic procedure for treatment of GERD.
K. Sumi, H. Inoue, Yasutoshi Kobayashi, Yugo Iwaya, Mary Raina Angeli Abad, Y. Fujiyoshi, Y. Shimamura, H. Ikeda, M. Onimaru   +8 more
semanticscholar   +1 more source

Proton pump inhibitors and osteoporosis

Current Opinion in Rheumatology, 2016
Purpose of review The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and ...
Andersen, Bjarne Nesgaard, Johansen, Per Birger, Abrahamsen, Bo   +2 more
openaire   +3 more sources

Potential proton pump inhibitor–related adverse effects

Annals of the New York Academy of Sciences, 2020
Proton pump inhibitors (PPIs) are one of the most common medications taken by patients worldwide. PPIs are used to treat acid‐related disorders, including gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection, and ...
I. E. Perry, I. Sonu, C. Scarpignato, J. Akiyama, M. Hongo, K. Vega   +5 more
semanticscholar   +1 more source

Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction.

European Heart Journal, 2019
AIMS Guidelines differ in their recommendations on therapy to prevent gastrointestinal bleeding for patients treated with dual antiplatelet treatment (DAPT).
T. Sehested, N. Carlson, P. Hansen, T. Gerds, M. Charlot, C. Torp-Pedersen, L. Køber, G. Gislason, M. Hlatky, E. Fosbøl   +9 more
semanticscholar   +1 more source